

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Solomon, L., et al.
Serial No.: 10/598,355
Filed: August 24, 2005
For: **SEGMENTED PHARMACEUTICAL DOSAGE FORMS**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

July 30, 2008

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, the reference listed on the accompanying Form PTO-1449 is hereby made of record for consideration by the Examiner in connection with the examination of the above-identified patent application.

Applicants respectfully note that this reference was cited in the International Preliminary Examination Report issued in connection with the international application, Appl'n No. PCT/US05/042120, corresponding to the above-referenced US application. A copy of the International Preliminary Examination Report is enclosed as Appendix A.

In accordance with the provisions of 37 C.F.R. 1.98(a)(2), the submission of a copy of the US Patent reference listed on the accompanying Form PTO-1449 is not required. If it is determined that a copy of this or any other reference is required or is missing, the Examiner is requested to contact the undersigned so that the missing copy, if any, may be forwarded.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97 (b), "[b]efore the mailing of a first Office Action on the merits." Accordingly, it is believed that no fee is due. In the event any fee is due in connection with filing of this Information Disclosure Statement, applicants respectfully request that the Examiner contact the undersigned for submission of such fee.

The Examiner is invited to contact the undersigned if additional information or clarification is needed.

Respectfully submitted,

July 30, 2018

By: 

Ted W. Whitlock
ACCU-BREAK Pharmaceuticals, Inc.
1000 South Pine Island Road
Suite 230
Plantation, Florida 33324
Ph: 954-236-7270
FAX: 954-236-7271